Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCBCI0901 in advanced solid tumors
NCT02151357Phase 1Terminated
- Sponsor
- Standard Chem & Pharm
- Start
- Aug 2014
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DCBCI0901 in solid tumor, sponsored by Standard Chem & Pharm. Primary endpoint: Safety and tolerability of multiple DCBCI0901 infusions at 1 year. Started Aug 2014; status: terminated.
02
Drugs
DCBCI0901
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02151357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151357.